{
  "docId": "019de070-fbaf-759b-8cbd-9f18172b1352",
  "docSlug": "7d8ead18d80cb869cda17e33a74aeb0b",
  "documentTitle": "BioNTech | Results Presentation Deck | 30 slides",
  "authorId": "biontech",
  "authorName": "BioNTech",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-05-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 9,
  "pageCount": 30,
  "prevPage": 8,
  "nextPage": 10,
  "slideType": "roadmap",
  "function": "plan_implementation",
  "density": "dense",
  "nDataPoints": 6,
  "notes": "The slide outlines a multi-arm clinical trial process involving prime and booster doses for both the original vaccine and a variant-specific version.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de070-fbaf-759b-8cbd-9f18172b1352/9",
  "deckHref": "/decks/019de070-fbaf-759b-8cbd-9f18172b1352",
  "deckJsonHref": "/decks/019de070-fbaf-759b-8cbd-9f18172b1352.json",
  "deckAnchorHref": "/decks/019de070-fbaf-759b-8cbd-9f18172b1352#slide-9",
  "components": [
    {
      "bbox": {
        "h": 0.45,
        "w": 0.92,
        "x": 0.04,
        "y": 0.45
      },
      "kind": "diagram",
      "text": "Clinical trial flow chart showing Prime, 1st Boost, and 2nd Boost stages for different participant groups.",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "efe853a1-9248-4ef9-bcfc-4295d4f7c53d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.92,
        "x": 0.04,
        "y": 0.28
      },
      "kind": "list",
      "text": "Expansion of global Phase 1/2/3 trials: 3rd dose to evaluate safety, magnitude and duration of immunity and variant protection; Variant specific booster to evaluate safety and immunogenicity of B.1.351 Spike version; Blueprint approach informs regulatory path.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "15a534a1-4067-4df6-b858-15cfc8c4a3a2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.92,
        "x": 0.04,
        "y": 0.18
      },
      "kind": "list",
      "text": "No evidence that adaptation of BNT162b2 is needed to date; Sera of BNT162b2 vaccinated individuals neutralize B.1.1.7 (UK), B.1.351 (SA), and P.1 (Brazilian) lineage in in vitro studies.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "321e0c65-5d7d-4396-877d-f9240d8a7558",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.45,
        "x": 0.07,
        "y": 0.93
      },
      "kind": "source-note",
      "text": "*B.117 (UK variant), B.1.351 (South African variant), and P.1 lineage (Brazilian variant) Liu et al., NEJM, Mar. 8, 2021",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ef38f3c8-3ad3-4d93-8e92-33420195bbc4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.92,
        "x": 0.04,
        "y": 0.08
      },
      "kind": "title",
      "text": "Preemptive Strategy to be Prepared for Addressing SARS-CoV-2 Variants",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "10689cd9-fce8-4e7f-a2d3-493ce263c8c0",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 16,
      "from": 9,
      "beatId": "ee869738-53c1-47a5-8d6b-a801587c68e3",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Satisfaction",
      "beatSlug": "monroes-sequence-satisfaction",
      "evidence": "The deck showcases progress on COVID-19 vaccine strategy and oncology innovation",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 16,
      "from": 5,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "acfebc91-ffe5-4ab0-8668-9619a540ee49",
      "evidence": "The deck explains the company's approach to immunotherapy and its potential",
      "position": 0,
      "objective": "Why BioNTech's immunotherapy approach is effective",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.6,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}